DNA
Bearish signalScored 2026-10-24 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
Research, not advice.
À propos
Ginkgo Bioworks Holdings, Inc.
- Nom
- Ginkgo Bioworks Holdings, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NYSE
- Capitalisation
- $664.0M
- Employés
- 485
- PDG
- Jason Kelly
- Site web
- https://www.ginkgo.bio
- Marché
- ARVNATXSAVBPIOVAMBXMGTX
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 73 051 titres (~725 646,29 $ US)
- Insiders
- Shetty Reshma P.Kelly Jason RHENRY CHRISTIAN O
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$962,482
Avg sell (VWAP, 90d window) $10.09 vs last close $10.02 (-0.7%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-10-19
- Liquidity
- Liquid $36,386,044/day · 20d vol
- Last synced
-
2026-10-26 21:10:23
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-19 | Canton Barry | Sell · S | 18,803 | $10.14 | $190,719 | Form 4 |
| 2026-10-19 | Coen Steven P. | Sell · S | 766 | $10.14 | $7,770 | Form 4 |
| 2026-10-19 | Kelly Jason R | Sell · S | 45,682 | $10.14 | $463,353 | Form 4 |
| 2026-10-19 | Shetty Reshma P. | Sell · S | 22,369 | $10.14 | $226,889 | Form 4 |
| 2026-10-05 | Coen Steven P. | Sell · S | 2,403 | $15.00 | $36,045 | Form 4 |
| 2026-09-15 | HENRY CHRISTIAN O | Sell · S | 5,000 | $7.08 | $35,405 | Form 4 |
| 2026-08-24 | Coen Steven P. | Sell · S | 330 | $6.98 | $2,302 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Bearish signalScored 2026-10-24 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
DNA presents a deeply distressed financial profile with persistent negative operating margins, severe cash burn, and a deteriorating balance sheet that overwhelms any near-term catalyst signal.
The first sentence of the analysis written for DNA on 2026-10-24 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Timing Supports a bullish reading. Interesting trend — weekly bias up
- Financial indicators Unavailable or mixed. Current ratio 4.92 · operating margin -185% — readings disagree
Suggested stop 7.86, nearest stored support minus 0.5 ATR(21.6% under the last close). Reward/risk to the next stored resistance is 0.24. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Recent news
- 2026-10-22 Hugging Face is launching a new AI model that lets scientists ''chat with DNA'' Hugging Face released a new AI model that allows users to "chat with DNA." Carbon-X can analyze and generate DNA and allows researchers to ask questions in plain language.
- 2026-10-21 Cerenome Announces New Dual Mechanism of Action Featuring Lethal DNA Damage and Beneficial Immunomodulation Supporting Lead Investigational Drug REYOBIQ™ Findings suggest a dual mechanism of action for REYOBIQ against cancer cells New findings revealed potential dual mechanism as combinations with checkpoint blockade further enhanced REYOBIQ therapeutic action in multiple cancers HOUSTON, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company") today announced that new preclinical data presented at the 16th Biennial Rivkin Ovarian Cancer Research Symposium illustrate the emerging immunomodulatory properties of REYOBIQ™ (rhenium Re186 obisbemeda), its lead investigational targeted radiotherapeutic. The Ovarian Cancer Research Alliance sponsored the symposium, held October 16–18, 2026, in Philadelphia.
- 2026-10-20 Ginkgo Bioworks Holdings, Inc. (DNA) Stock Falls Amid Market Uptick: What Investors Need to Know Ginkgo Bioworks Holdings, Inc. (DNA) reached $9.86 at the closing of the latest trading day, reflecting a -2.09% change compared to its last close.
- 2026-10-14 Here''s Why Ginkgo Bioworks Holdings, Inc. (DNA) Fell More Than Broader Market In the most recent trading session, Ginkgo Bioworks Holdings, Inc. (DNA) closed at $11.53, indicating a -1.96% shift from the previous trading day.
- 2026-10-09 What''s Going on With Ginkgo Bioworks Stock on Friday? Ginkgo Bioworks Inc. (NYSE:DNA) is strengthening national biotechnology infrastructure by granting remote laboratory access through the National Science Foundation''s X-Labs program and integrating high-speed cellular imaging tools into its Boston facility.
- 2026-10-08 Araceli Biosciences und Ginkgo Bioworks ermöglichen die zelluläre Bildgebung in großem Maßstab für das „Lab-in-the-Loop"-System von Nebula /PRNewswire/ -- Araceli Biosciences und Ginkgo Bioworks (NYSE: DNA) gaben heute die Integration des Endeavor-High-Content-Imaging-Geräts von Araceli in
- 2026-10-08 Ginkgo Bioworks to Provide Autonomous Lab Access to NSF X-Labs Researchers, Contributing Cloud Lab Time and Protein Testing Services to $1.5 Billion Breakthrough Science Program BOSTON--(BUSINESS WIRE)--Ginkgo Bioworks (NYSE: DNA) today announced that it will provide in-kind access to its autonomous laboratory in Boston to support the National Science Foundation''s X-Labs program. Ginkgo''s support was announced today by Michael Kratsios, Director of the White House Office of Science and Technology Policy (OSTP), at the Science: A New Golden Age Summit in Washington, D.C. NSF X-Labs is a $1.5 billion, decade-long initiative to fund independent teams of researchers, engin.
- 2026-10-08 Araceli Biosciences y Ginkgo Bioworks incorporan la obtención de imágenes celulares al laboratorio de Nebula /PRNewswire/ -- Araceli Biosciences y Ginkgo Bioworks (NYSE: DNA) han dado a conocer hoy la integración del instrumento de imágenes de alto contenido Endeavor
- 2026-10-08 Araceli Biosciences and Ginkgo Bioworks Bring Cellular Imaging at Scale to Nebula''s Lab-in-the-Loop The Endeavor® adds the fastest high-content cellular data generation to Ginkgo''s around-the-clock research PORTLAND, Ore. and BOSTON, Oct. 8, 2026 /PRNewswire/ -- Araceli Biosciences and Ginkgo Bioworks (NYSE: DNA) today announced the integration of Araceli''s Endeavor® high-content imaging instrument into Nebula, Ginkgo''s autonomous lab in Boston.
- 2026-10-07 Ginkgo Bioworks Holdings, Inc. (DNA) Falls More Steeply Than Broader Market: What Investors Need to Know Ginkgo Bioworks Holdings, Inc. (DNA) closed the most recent trading day at $11.47, moving 7.57% from the previous trading session.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 81.5% | 83.0% | 78.5% | 57.3% | 58.7% | |
| Ebit Margin | -184.3% | -241.1% | -355.1% | -444.1% | -584.9% | |
| Ebitda Margin | -149.6% | -213.3% | -326.6% | -435.2% | -575.7% | |
| Operating Profit Margin | -185.3% | -246.5% | -343.8% | -462.4% | -582.6% | |
| Pretax Profit Margin | -184.3% | -241.1% | -355.1% | -444.1% | -585.7% | |
| Continuous Operations Profit Margin | -183.8% | -240.9% | -355.1% | -440.9% | -585.2% | |
| Net Profit Margin | -183.8% | -240.9% | -355.1% | -440.6% | -583.1% | |
| Bottom Line Profit Margin | -183.8% | -240.9% | -355.1% | -440.6% | -601.8% | |
| Current Ratio | 4.917 | 5.619 | 6.113 | 8.384 | 12.786 | |
| Quick Ratio | 4.917 | 5.619 | 6.113 | 8.359 | 12.761 | |
| Solvency Ratio | -0.415 | -0.732 | -1.445 | -2.568 | -3.576 | |
| Cash Ratio | 1.742 | 5.235 | 5.761 | 7.607 | 11.502 | |
| Price To Earnings Ratio | -1.473 | -0.932 | -3.680 | -1.348 | -6.175 | |
| Price To Earnings Growth Ratio | 0.032 | 0.022 | 0.058 | 0.197 | -0.005 | |
| Forward Price To Earnings Growth Ratio | 0.032 | 0.022 | 0.058 | 0.197 | -0.005 | |
| Price To Earnings Diluted Ratio | -1.473 | -0.932 | -3.674 | -1.347 | -5.986 | |
| Price To Earnings Diluted Growth Ratio | 0.032 | 0.022 | 0.058 | 0.140 | -0.005 | |
| Price To Book Ratio | 0.906 | 0.712 | 2.990 | 1.633 | 7.277 | |
| Price To Sales Ratio | 2.708 | 2.245 | 13.045 | 5.934 | 34.903 | |
| Price To Free Cash Flow Ratio | -2.579 | -1.334 | -9.754 | -9.310 | -35.296 | |
| Price To Operating Cash Flow Ratio | -2.694 | -1.595 | -11.101 | -11.240 | -43.156 | |
| Debt To Assets Ratio | 0.393 | 0.340 | 0.144 | 0.174 | 0.011 | |
| Debt To Equity Ratio | 0.865 | 0.653 | 0.218 | 0.255 | 0.015 | |
| Debt To Capital Ratio | 0.464 | 0.395 | 0.179 | 0.203 | 0.015 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 2.202 | 1.924 | 1.518 | 1.463 | 1.376 | |
| Working Capital Turnover Ratio | 0.391 | 0.341 | 0.238 | 0.333 | 0.323 | |
| Operating Cash Flow Ratio | -1.782 | -2.979 | -1.803 | -1.458 | -1.883 | |
| Operating Cash Flow Sales Ratio | -1.005 | -1.408 | -1.175 | -0.528 | -0.809 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.045 | 1.196 | 1.138 | 1.207 | 1.223 | |
| Debt Service Coverage Ratio | 0.000 | -5,148.032 | -8,830.344 | -19,469.000 | -760.722 | |
| Interest Coverage Ratio | 0.000 | -5,954.862 | -9,294.688 | -20,839.170 | -770.530 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -0.389 | -0.683 | -1.235 | -0.570 | -11.021 | |
| Capital Expenditure Coverage Ratio | -22.317 | -5.110 | -7.242 | -4.825 | -4.491 | |
| Dividend Paid And Capex Coverage Ratio | -22.317 | -5.110 | -7.242 | -4.825 | -4.491 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -2.881 | -0.858 | -3.136 | -0.944 | -5.218 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 81.5% | ▼-1.6% | ▲9.7% |
| Ebit Margin | -184.3% | ▲56.8% | ▲177.6% |
| Ebitda Margin | -149.6% | ▲63.7% | ▲190.5% |
| Operating Profit Margin | -185.3% | ▲61.3% | ▲178.8% |
| Pretax Profit Margin | -184.3% | ▲56.8% | ▲177.8% |
| Continuous Operations Profit Margin | -183.8% | ▲57.1% | ▲177.4% |
| Net Profit Margin | -183.8% | ▲57.1% | ▲176.9% |
| Bottom Line Profit Margin | -183.8% | ▲57.1% | ▲180.6% |
| Current Ratio | 4.917 | ▼-0.703 | ▼-2.647 |
| Quick Ratio | 4.917 | ▼-0.703 | ▼-2.637 |
| Solvency Ratio | -0.415 | ▲0.317 | ▲1.332 |
| Cash Ratio | 1.742 | ▼-3.493 | ▼-4.627 |
| Price To Earnings Ratio | -1.473 | ▼-0.542 | ▲1.248 |
| Price To Earnings Growth Ratio | 0.032 | ▲0.010 | ▼-0.029 |
| Forward Price To Earnings Growth Ratio | 0.032 | ▲0.010 | ▼-0.029 |
| Price To Earnings Diluted Ratio | -1.473 | ▼-0.542 | ▲1.209 |
| Price To Earnings Diluted Growth Ratio | 0.032 | ▲0.010 | ▼-0.018 |
| Price To Book Ratio | 0.906 | ▲0.195 | ▼-1.797 |
| Price To Sales Ratio | 2.708 | ▲0.464 | ▼-9.059 |
| Price To Free Cash Flow Ratio | -2.579 | ▼-1.245 | ▲9.076 |
| Price To Operating Cash Flow Ratio | -2.694 | ▼-1.099 | ▲11.263 |
| Debt To Assets Ratio | 0.393 | ▲0.053 | ▲0.181 |
| Debt To Equity Ratio | 0.865 | ▲0.212 | ▲0.464 |
| Debt To Capital Ratio | 0.464 | ▲0.069 | ▲0.213 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 2.202 | ▲0.278 | ▲0.505 |
| Working Capital Turnover Ratio | 0.391 | ▲0.050 | ▲0.065 |
| Operating Cash Flow Ratio | -1.782 | ▲1.197 | ▲0.199 |
| Operating Cash Flow Sales Ratio | -1.005 | ▲0.402 | ▼-0.020 |
| Free Cash Flow Operating Cash Flow Ratio | 1.045 | ▼-0.151 | ▼-0.117 |
| Debt Service Coverage Ratio | 0.000 | ▲5148.032 | ▲6841.620 |
| Interest Coverage Ratio | 0.000 | ▲5954.862 | ▲7371.850 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -0.389 | ▲0.294 | ▲2.391 |
| Capital Expenditure Coverage Ratio | -22.317 | ▼-17.207 | ▼-13.520 |
| Dividend Paid And Capex Coverage Ratio | -22.317 | ▼-17.207 | ▼-13.520 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -2.881 | ▼-2.023 | ▼-0.274 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $460.9M | $509.6M | $3.28B | $2.83B | $10.95B | |
| Enterprise value | $733.5M | $415.8M | $2.58B | $1.96B | $9.43B | |
| EV / Sales | 4.31x | 1.83x | 10.24x | 4.11x | 30.04x | |
| EV / Op. cash flow | -4.29x | -1.30x | -8.72x | -7.78x | -37.14x | |
| EV / Free cash flow | -4.10x | -1.09x | -7.66x | -6.44x | -30.38x | |
| EV / EBITDA | -2.88x | -0.86x | -3.14x | -0.94x | -5.22x | |
| Net debt / EBITDA | -1.07x | 0.19x | 0.86x | 0.42x | 0.84x | |
| Current ratio | 4.92x | 5.62x | 6.11x | 8.38x | 12.79x | |
| Income quality | 0.55x | 0.58x | 0.33x | 0.12x | 0.14x | |
| Graham net-net | -$3 | -$2 | $8 | $14 | $35 | |
| Tax burden | 99.7% | 99.9% | 100.0% | 99.2% | 99.6% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.1% | |
| Working capital | $375.9M | $495.5M | $837.9M | $1.28B | $1.59B | |
| Invested capital | $961.5M | $1.17B | $1.36B | $2.17B | $1.78B | |
| Return on assets | -27.9% | -39.7% | -53.6% | -82.9% | -88.4% | |
| Operating ROA | -25.3% | -36.8% | -41.1% | -95.8% | -133.2% | |
| Return on tangible assets | -29.4% | -41.9% | -58.2% | -88.9% | -90.2% | |
| Return on equity | -61.5% | -76.4% | -81.4% | -121.2% | -121.6% | |
| Return on invested capital | -30.0% | -43.0% | -56.9% | -91.6% | -94.3% | |
| Return on capital employed | -30.8% | -44.1% | -57.6% | -93.3% | -94.4% | |
| Earnings yield | -67.9% | -107.3% | -27.2% | -74.3% | -16.7% | |
| Free cash flow yield | -38.8% | -75.0% | -10.3% | -10.7% | -2.8% | |
| Capex / Op. cash flow | -4.5% | -19.6% | -13.8% | -20.7% | -22.3% | |
| Capex / Depreciation | 13.0% | 99.2% | 57.0% | 122.8% | 194.4% | |
| Capex / Sales | 4.5% | 27.5% | 16.2% | 10.9% | 18.0% | |
| SG&A / Sales | 107.7% | 108.4% | 153.1% | 299.3% | 275.0% | |
| R&D / Sales | 143.3% | 186.8% | 230.9% | 220.4% | 366.3% | |
| Stock comp / Sales | 47.9% | 49.5% | 91.4% | 404.1% | 511.7% | |
| Intangibles / Total assets | 5.1% | 5.3% | 7.9% | 6.7% | 2.1% | |
| Days sales outstanding | 52d | 36d | 26d | 64d | 174d | |
| Days payables outstanding | 122d | 134d | 63d | 19d | 23d | |
| Operating cycle | 52d | 36d | 26d | 72d | 184d | |
| Cash conversion cycle | -71d | -98d | -37d | 53d | 161d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years